Companies › Turning Point Therapeutics
2 active drug programs in 6 registered trials: 4 Phase 1, 2 Phase 2; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| elzovantinib (TPX-0022) MET/CSF1R/SRC inhibitor | MET, CSF1R, SRC | Phase 1 | Advanced Solid Tumor | Mar 2027 |
| Repotrectinib (TPX-0005) Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor | NTRK1, NTRK2, ROS1, NTRK3, CD74 | Phase 1 | Locally Advanced Solid Tumors; NSCLC; NSCLC Stage IV; Advanced Cancer | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03993873 | elzovantinib (TPX-0022) | Phase 1 | Advanced Solid Tumor | Oncology | Mar 2027 |
| NCT06315010 | Repotrectinib (TPX-0005) | Phase 2 | NSCLC | Oncology | Mar 2027 |
| NCT04094610 | Repotrectinib (TPX-0005) | Phase 1 | Locally Advanced Solid Tumors | Oncology | Sep 2027 |
| NCT03093116 | Repotrectinib (TPX-0005) | Phase 1 | Locally Advanced Solid Tumors | Oncology | Feb 2028 |
| NCT05004116 | Repotrectinib (TPX-0005) | Phase 1 | Advanced Cancer | Oncology | Aug 2028 |
| NCT06552234 | Repotrectinib (TPX-0005) | Phase 2 | NSCLC Stage IV | Oncology | Sep 2031 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.